Department of Urology, University of Florida, Jacksonville, FL.
Department of Urology, University of Florida, Jacksonville, FL.
Urol Oncol. 2022 Feb;40(2):45-55. doi: 10.1016/j.urolonc.2021.11.008. Epub 2021 Dec 9.
To investigate the accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) in detection of muscle-invasive bladder cancer (MIBC) we performed a systematic review and meta-analysis of the available literature.
Scopus, Web of Science, PubMed, and EMBASE were searched up to 8 March 2021 for the studies evaluating the diagnostic performance of VI-RADS for the detection of MIBC. Inclusion criteria were patients with bladder cancer; index test of VI-RADS based on multiparametric MRI; reference test of histopathological findings from TURBT, re-TURBT, or cystectomy and study design of cohort. Case reports, review articles, and editorials were eliminated, as well as studies with insufficient knowledge to acquire TP, FP, FN, and TN values of VI-RADS. The MIDAS module of STATA was for statistical analysis. The heterogeneity was explored using subgroup analysis and meta-regression analysis.
Overall, 22 eligible studies, consisting of 2,576 participants and 5,414 MRI reports, were included in this meta-analysis. The area under curve (AUC) of VI-RADS at cut-point values of 3 and 4 were 0.93 (95%CI: 0.91, 0.95), 0.93 (95%CI: 0.90, 0.95), respectively. Based on Youden's J statistic, the optimal VI-RADS cutoff value for predicting MIBC was determined as 3 which granted a pooled sensitivity of 89% (95%CI: 87%, 91%; I=48%) and a specificity of 84% (95%CI: 80%, 87%; I=90%). Based on meta-regression, the sources of inter-study heterogeneity for VI-RADS ≥ 3 were the sample size > 70, study design, single-center vs multi-center, patient population characteristics (i.e., gender, age), reference standard, histology, magnetic strength, T2WI slice thickness, and the number of radiologists reporting the MRI results (P value ≤ 0.01).
The VI-RADS demonstrates consistently high diagnostic accuracy to predict MIBC. This scoring system could be applied in standard staging MRI reports of bladder cancer and can be incorporated into future MIBC work up guidelines.
为了评估 Vesical Imaging-Reporting and Data System(VI-RADS)在检测肌层浸润性膀胱癌(MIBC)中的准确性,我们对现有文献进行了系统评价和荟萃分析。
截至 2021 年 3 月 8 日,我们在 Scopus、Web of Science、PubMed 和 EMBASE 数据库中检索了评估 VI-RADS 检测 MIBC 的诊断性能的研究。纳入标准为:膀胱癌患者;基于多参数 MRI 的 VI-RADS 指数试验;经 TURBT、再 TURBT 或膀胱切除术获得的组织病理学检查结果作为参考标准;且研究设计为队列研究。排除病例报告、综述文章和社论,以及无法获取 VI-RADS 的 TP、FP、FN 和 TN 值的研究。使用 STATA 的 MIDAS 模块进行统计分析。采用亚组分析和 meta 回归分析探索异质性。
共有 22 项符合条件的研究,包含 2576 名参与者和 5414 份 MRI 报告,纳入了本次荟萃分析。在 VI-RADS 截断值为 3 和 4 时,曲线下面积(AUC)分别为 0.93(95%CI:0.91,0.95)和 0.93(95%CI:0.90,0.95)。根据 Youden 的 J 统计量,预测 MIBC 的最佳 VI-RADS 截断值为 3,此时合并敏感度为 89%(95%CI:87%,91%;I=48%),合并特异度为 84%(95%CI:80%,87%;I=90%)。meta 回归分析显示,VI-RADS≥3 时的研究间异质性来源为样本量>70、研究设计、单中心与多中心、患者人群特征(即性别、年龄)、参考标准、组织学、磁场强度、T2WI 层厚和报告 MRI 结果的放射科医生数量(P 值均≤0.01)。
VI-RADS 对预测 MIBC 具有较高的诊断准确性。该评分系统可应用于膀胱癌标准分期 MRI 报告,并可纳入未来 MIBC 工作指南。